Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of erdafitinib in advanced solid tumors with FGFR gene alterations
2019-002113-19Phase 2Unknown
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of erdafitinib in Non-hematologic malignancy (2 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoint: Overall response rate by IRC. Status: unknown.
02
Drugs
erdafitinib
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on 2019-002113-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002113-19.